bullish FDA clearance for product that can be used on 600,000 patients
$BTGGF recent news/filings
## source: finance.yahoo.com
Fri, 23 May 2014 08:49:05 GMT ~ STOCKS NEWS EUROPE-BTG jumps on FDA nod for embolism treatment
[Reuters - UK Focus] - Shares in BTG Plc climb 8.5 percent to the top Britain's FTSE-250 midcap index after the British pharmaceutical firm says its device used to treat pulmonary embolism has won clearance from the U.S. FDA. ...
Fri, 28 Mar 2014 20:28:06 GMT ~ Canada to remove foreign investment limit on Nordion
[Reuters - UK Focus] - OTTAWA/WINNIPEG, March 28 (Reuters) - The Canadian government will remove the 25-percent foreign investment cap on medical isotope provider Nordion Inc (Toronto: NDN.TO - news) in cases that are deemed to be of net benefit to Canada, under legislation introduced on Friday. "The foreign ownership restrictions with respect to the company were put in place when it was privatized in the early 1990s, and do not serve an ongoing purpose," said Melissa Lantsman, spokeswoman for Finance Minister Joe Oliver. "The removal of the foreign ownership restrictions will allow Nordion to access more investment capital, enabling it to better grow and create jobs, but is conditional on approval of a transaction under the Investment Canada Act."
Fri, 31 Jan 2014 20:44:44 GMT ~ Brazil's BTG plans first LME warehouse in Owensboro, Ky.
[Reuters - UK Focus] - Brazil's largest independent investment bank, Grupo BTG Pactual SA and Pacorini Metals, owned by Glencore Xstrata PLC (Other OTC: GLCNF - news) , will run the London Metal Exchange's latest U.S. warehousing facility, the port operator told Reuters on Friday. Owensboro Riverport Authority in Kentucky has chosen the two firms to lease and operate sheds with an initial capacity for about 120,000 tonnes of aluminum, the port's Chief Executive Brian Wright said. The port has room to store more metal if needed, he said. Both companies will now apply to the LME for go ahead to store metal within its network.
Link: http://www.otcmarkets.com/stock/BTGGF/company-info Ticker: $BTGGF OTC Market Place: OTC Pink Current CIK code: not found Company name: BTG plc Company website: http://www.btgplc.com Incorporated In: United Kingdom
Business Description: We are a growing international specialist healthcare company. Our mission is to bring to market medical products that meet the needs of specialist healthcare physicians and their patients.
$BTGGF share structure
## source: otcmarkets.com
Market Value: $3,224,075,000 a/o Nov 28, 2014 Shares Outstanding: 257,926,000 a/o Jun 30, 2010 Float: Not Available Authorized Shares: Not Available Par Value: No Par Value $BTGGF extra dd links
Company name: BTG plc Company website: http://www.btgplc.com
5 Fleet Place
London, EC4M 7RD
Phone: 44 20 7575 0000
Fax: 44 20 7575 0010
BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.